Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Celecoxib, Creatine, Minocycline
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 15 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, double-unit umbilical cord blood transplantation, total-body irradiation, tacrolimus, peripheral blood stem cell transplantation
Drug · Procedure · Radiation
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed Phase 4 Interventional Results available

Effects of Isotretinoin on CYP2D6 Activity

NCT03076021
Conditions
CYP2D6 Polymorphism
Interventions
Isotretinoin, dextromethorphan
Drug
Lead sponsor
University of Washington
Other
Eligibility
12 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Crohn's Disease
Interventions
Serum-derived Bovine Immunoglobulin / Protein Isolate, Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
North Little Rock, Arkansas • Hollywood, Florida • Winter Park, Florida + 3 more
Completed Phase 4 Interventional Results available

Orphenadrine and Methocarbamol for LBP

NCT02665286
Conditions
Low Back Pain
Interventions
Orphenadrine, Methocarbamol, Naproxen, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Kidney Calculi, Kidney Diseases, Nephrolithiasis, Urolithiasis, Ureteral Diseases, Ureteral Calculi
Interventions
Methocarbamol, Oxybutynin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Overweight, Obesity
Interventions
Standard Diet, Ketogenic Diet, Placebo, Nicotinamide Riboside
Other · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide Disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
95
States / cities
Birmingham, Alabama • Tempe, Arizona • Fayetteville, Arkansas + 82 more
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
88
States / cities
Tempe, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 74 more
Conditions
Acute Respiratory Infection
Interventions
Mucinex, Placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI)
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

Mucinex® for Treatment of Filamentary Keratitis

NCT02859246
Conditions
Filamentary Keratitis
Interventions
Mucinex®
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Treatment of Acute Sinusitis

NCT00377403
Conditions
Acute Respiratory Infections, Acute Rhinosinusitis
Interventions
Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions
R932333, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
Conditions
Acute Respiratory Infection, Bronchitis, Rhinosinusitis
Interventions
Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)
Drug
Lead sponsor
Adams Respiratory Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Carmichael, California • Torrance, California + 24 more
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Conditions
Chronic Rhinitis
Interventions
Placebo, Guaifenesin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Friedreich's Ataxia
Interventions
alpha-tocopherolquinone (A0001), placebo
Drug
Lead sponsor
Penwest Pharmaceuticals Co.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Mucinex Exploratory Cold Study

NCT01046136
Conditions
Common Cold
Interventions
guaifenesin (Mucinex), placebo
Drug
Lead sponsor
Reckitt Benckiser Inc.
Industry
Eligibility
12 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bellevue, Nebraska
Completed Not applicable Interventional Accepts healthy volunteers

Glycomacropeptide and Women's Health

NCT05551091
Conditions
Obesity
Interventions
glycomacropeptide (GMP)
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 90 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Lichen Sclerosus
Interventions
Delgocitinib, Cream Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 3 more
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Serum-Derived Bovine Immunoglobulin, Placebo
Dietary Supplement · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Farmington, Connecticut
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

NCT03480009
Conditions
Abortion in First Trimester
Interventions
Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone
Drug
Lead sponsor
Study Investigator-Sponsor
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Bronchitis
Interventions
Guafenesin tablets
Drug
Lead sponsor
American Health Research
Other
Eligibility
40 Years to 90 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Charlotte, North Carolina • Rock Hill, South Carolina